Home › Gastro-enteropancreatic neuroendocrine tumor
Gastro-enteropancreatic neuroendocrine tumor clinical trials recruiting in the U.S.
8 studies for Gastro-enteropancreatic neuroendocrine tumor are recruiting participants at sites across the United States.
Cities with the most studies
- Jacksonville, FL3 studies
- Nashville, TN3 studies
- Cedar Rapids, IA3 studies
- St. Louis, MO3 studies
- Columbus, OH3 studies
- Lexington, KY3 studies
By state
- Florida4 studies
- Iowa3 studies
- Kentucky4 studies
- Missouri3 studies
- Ohio4 studies
- Tennessee3 studies
- Texas3 studies
- Virginia3 studies
- Washington3 studies
Recently updated studies
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
RecruitingPhase 1
24 Months – 18 Years · All sexes · Updated Sep 25, 2026 · NCT06441331Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT07165132Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
RecruitingPhase 3
Ages 12 to 100 · All sexes · Updated Sep 11, 2026 · NCT06784752A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
RecruitingObservational study
Ages 18 to 110 · All sexes · Updated Jul 6, 2026 · NCT07635316Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
RecruitingPhase 1/2
Ages 18 to 90 · All sexes · Updated May 14, 2026 · NCT05636618Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Mar 30, 2026 · NCT05477576Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors
RecruitingObservational study
Ages 18 and older · All sexes · Updated Mar 20, 2026 · NCT04090034Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 2, 2026 · NCT07150546From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.